Oct 25, 2023 / 08:15PM GMT
Operator
Good day, and thank you for standing by. Welcome to the Anaptys PD-1 Agonist Rosnilimab R&D Event Webcast. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to Dan Faga, President and Chief Executive Officer of Anaptys.
Daniel R. Faga - AnaptysBio, Inc. - President, CEO & Director
Welcome, everyone. We are excited to host today's event focused on rosnilimab, our internally discovered PD-1 agonist. This presentation will contain statements that are forward looking. We're going to review what are massive opportunities for rosnilimab with a best-in-class profile in rheumatoid arthritis, where there is proof-of-concept for this mechanism and announcing today a first-in-class study in ulcerative colitis.
Joining me from Anaptys are Dr. Paul Lizzul, our Chief Medical Officer; Dr. Martin Dahl, our SVP of Research; and Dr. Cailin Sibley, our VP, Translational Medicine. Also, we've had 2 distinguished physicians prerecord their sessions. Dr. Jonathan Graf, Professor
AnaptysBio Inc to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
